The Business Research Company’s report on the Meningococcal Vaccines Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the meningococcal vaccines market further?
An increase in healthcare spending is expected to propel the growth of the meningococcal vaccine market going forward. Healthcare refers to a residential care institution, nursing facility, intermediate care facility for people with mental illnesses, or intermediate care facility for people with mental retardation. The high expense of new vaccine generations compared to their predecessors has become a key factor in discussions about whether the benefits of the new vaccinations justify their prices. Assessing the complete social and economic advantages of vaccination is becoming an increasingly important area of investigation in the literature on valuing vaccination. For instance, in May 2022, according to an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, healthcare spending in the United States had risen by 9.7% to $4.1 trillion, or $12,530 per person. This pace of growth is significantly higher than 2019’s (4.3%). Therefore, an increase in healthcare spending is driving the growth of the meningococcal vaccine market.
Access Your Free Sample of the Global Meningococcal Vaccines Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp
What are the key factors influencing the forecasted market size of the meningococcal vaccines industry?
The meningococcal vaccines market size has grown rapidly in recent years. It will grow from $3.89 billion in 2024 to $4.29 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to disease incidence, global travel trends, healthcare infrastructure, epidemic preparedness, health insurance coverage.
The meningococcal vaccines market size is expected to see strong growth in the next few years. It will grow to $6.18 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to emergence of new strains, increasing globalization, growing healthcare investments, health initiatives, changing regulatory landscape. Major trends in the forecast period include personalized vaccines, digital vaccination records, gene editing technologies, multi-valent vaccines, subscription-based vaccine models.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp
Who are the leading competitors in the meningococcal vaccines market?
Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.
Which emerging trends are set to transform the meningococcal vaccines market landscape?
Major companies operating in the meningococcal vaccines market are developing new vaccines for the prevention of serogroups to increase their profitability in the market. Meningococcal vaccines are preventive measures designed to protect individuals against infections caused by specific serogroups of the bacteria Neisseria meningitidis. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company received approval from FDA for the vaccine PENBRAYA. PENBRAYA, with extensive serogroup coverage, is the most comprehensive U.S.-approved meningococcal vaccine, safeguarding against groups A, B, C, W, and Y. FDA approval is grounded in robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity to Trumenba + Menveo across all serogroups, coupled with favorable safety. Pfizer’s September 2022 announcement revealed positive outcomes from a Phase 3 trial, comparing PENBRAYA to existing licensed meningococcal vaccines in terms of safety, tolerability, and immunogenicity.
How do different geographies compare in terms of market share and growth potential in the meningococcal vaccines market?
North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report
Which major segments of the meningococcal vaccines market are experiencing the fastest growth?
The meningococcal vaccines market covered in this report is segmented –
1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine
2) By Serotype: Men Acwy, Men B/Bc, Men C
3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults
4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels
5) By End user: Hospitals, Research, Academic Institutes
Subsegments:
1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine
2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine
3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8013
What defines the structure and scope of the meningococcal vaccines market?
Meningococcal vaccinations are vaccines that protect against meningococcal meningitis, an infection with the bacterium Neisseria meningitides that leads to inflammation of the tissues that surround the brain and spinal cord.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
